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Human pituitary tumor-transforming gene (hPTTG1) is a human securin homolog. It functions as a
mitosis regulator during cell cycle progression in normal cells. It is also an oncogenic transcription factor.
Deletion of the PTTG1 gene or its overexpression causes chromosome instability, increasing the proba-
bility of tumor formation and metastasis. PTTG1 has been found to be overexpressed in most human
carcinomas with metastatic grade and blastic leukemia. Thus, overexpressed PTTG1 is suspected to
promote tumor metastasis. However, the mechanism by which overexpressed PTTG1 drives tumor cells
into metastasis remains unclear, but it is assumed to occur through activation of its target genes involved
in the metastasis processes. Among the PTTG1-activated genes, GEFH1 and CXCR2 were shown to be
directly regulated by PTTG1. Molecular biological studies and examination of human tumor samples
indicated that overexpressed PTTG1 promotes tumor metastasis through activation of GEFH1/RhoA
signaling, resulting in remodeling of cytoskeletal dynamics, enhancing the invasiveness of cancer cells,
and driving tumor cells toward metastasis in vivo. Overexpressed PTTG1 can also activate CXCR2, which
usually induces senescence in cancer cells if the CXCR2/p21 senescence pathway is functional. However,
in most malignant tumor cells in which the CXCR2/p21 senescence pathway is defective, these tumor cells
escape senescence and move toward metastasis. In these cells, overexpressed PTTG1 directly activates
CXCR2 and its ligands, interleukin-8 (IL-8), and Gro-a or indirectly activates nuclear factor-kB to activate
IL-8 and Gro-a. These cytokines, in turn, recruit inﬂammatory cells to the tumor sites creating micro-
environments that favor tumor metastasis. Thus, PTTG1-overexpressed cancer cells can use myriad
pathways to execute metastasis. It is important to screen for inhibitors that can neutralize the functions
of overexpressed PTTG1. These inhibitors could be signiﬁcant in the therapeutic arsenal against meta-
static cancers.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Perturbation of the genetic constitution of cells disturbs regu-
latory circuitries leading to the appearance of cancer cells [1]. The
genetic changes leading to cancer can occur in sequential steps
with mutations, deletions, or ampliﬁcations. Eventually, cancer
cells break out of the conﬁnement of their adjacent tissues and
travel to distant speciﬁc sites where they establish new colonies.
This disseminated metastasis contributes to the majority of cancer
deaths [2]. The genetic, cellular, and molecular bases of metastasis
remain elusive. At present, we know at least several well-
orchestrated processes are involved in metastasis as follows: (1)iology and Human Genetics,
ualien, Taiwan. Tel.: þ886 03
ddhist Compassion Relief Tzu Chiactivation of epithelialemesenchymal transition [3], (2) remodel-
ing of extracellular matrix [4], (3) migration of tumor cells to spe-
ciﬁc secondary sites [5], and (4) neoangiogenesis [6]. It is pertinent
and clinically important to identify gene sets or “signatures” so that
the mechanisms of metastasis can be illustrated. With advances in
genomic studies, knowledge about these genes and pathways
involved in tumor metastasis has started to evolve, and sets or
groups of genes closely associatedwith tumormetastasis have been
revealed. Human PTTG1 (hPTTG1) is one of the candidate signature
molecules for metastasis [7].
hPTTG1, a human securin, was initially isolated from a rat pitu-
itary tumor cell line [8]. Subsequently, its human homolog was
isolated from fetal liver and several tumor cell lines [9e11]. hPTTG1
has a cell cycle-dependent expression pattern [12]. It functions as
securin protein [12]. Like vertebrate securin, hpttg1 is subject to
ubiquitin-mediated degradation at the end of metaphase [12]. The
hPTTG1 gene encodes for a small protein of 202 amino acids. Hpttg1
has been detectedmost abundantly in fetal liver, testis, and thymus,Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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hPTTG1 can transform NIH 3T3 cells that form tumors when
transplanted into nude mice [8]. Thus, hPTTG1 behaves as an
oncogene. Indeed, hPTTG1 is overexpressed in most invasive solid
tumors and hematopoietic neoplasia [9,11,13e15]. This has been
further conﬁrmed by a microarray analysis of comparative
expression proﬁles between metastatic and nonmetastatic carci-
noma from patients [7]. Therefore, hPTTG1 appears to drive tumor
cells into metastasis; however, direct evidence that overexpressed
hPTTG1 promotes metastasis of human carcinoma is still lacking.
The promotion of metastasis by hPTTG1 may ostensibly be
through dysfunction of its degradation, allowing it to accumulate
and subsequently exert its metastatic functions. Normally, for a cell
to proceed through mitosis, securin (pttg1) must be degraded by
activated anaphase promoting complex/CDC20 (APC/CDC20) at the
onset of anaphase. In metastatic cancer cells, the degradation
process may be deﬁcient, resulting in excessive pttg1 and conse-
quently, induction of chromosome instability and aneuploidy, and
cell proliferation. In cells with high levels of hpttg1, the metaphase
to anaphase transition is blocked and asymmetrical cytokinesis
without chromosome segregation or chromosome decondensation
without cytokinesis has been observed [16]. There is frequent
chromosome loss in cells depleted of the hPTTG1 gene [17]. The
effect, however, was found to be transient; after 12 passages, the
karyotype in hPTTG1 knockout cells was found to be the same as
wild-type cells. This suggests additional compensatory mecha-
nisms for chromosome segregation in human cells [18]. There ap-
pears to be a range in the amount of hpttg1 needed to maintain
normal chromosomal ploidy. Outside of this range, cells are driven
to chromosome instability, increasing the probability of tumor
formation and metastasis.
2. Genes regulated by hPTTG1
PTTG1 can function as a transcription factor [9,19]. The onco-
genesmyc and bFGFwere initially identiﬁed as its directly regulated
genes [20]. Chip-on-chip analysis, however, showed elevated
hpttg1 binding to the promoters of 746 genes [21]. The results
suggest that hpttg1 regulates a wide range of genes. In addition,
hpttg1 can interact with a variety of proteins as well. In addition to
separase, hpttg1 was found to be associated with PBF, PP2A, Ku70/
80, and p53 [22e25].
For an overexpressed PTTG1 gene to promote metastasis, it
presumably can activate genes involved in themetastatic processes.
We have identiﬁed ﬁbroblast growth factor receptor (FGFR), uro-
kinase plasminogen activator (uPA), CXCR2, and GEFH1, among
others that are upregulated in hPTTG1-overexpressed cells. FGFR is
well known to be involved in angiogenesis, which is important in
tumor metastasis [26]. It has been identiﬁed as an hPTTG1 directly
regulated gene [19]. uPA, a protease, plays a key role in remodeling
of extracellular matrix to promote tumor metastasis [27]. Our
studies indicated that hPTTG1 indirectly activates this gene. CXCR2,
like CXCR4 and CCR7, is an important G-protein-coupled receptor in
chemotaxis, the process adapted by metastatic tumor cells to
migrate to speciﬁc secondary sites [28]. GEF regulates Rho family
proteins that control cell migration and invasiveness, and plays an
important role in promoting tumor metastasis [29]. Our studies
indicated that GEFH1 and CXCR2 are the genes directly regulated by
hPTTG1. Therefore, the elucidation of how these two genes function
in tumor metastasis would explain why hPTTG1 is overexpressed in
most metastatic carcinomas.
CXCR2 is activated by multiple CXC chemokines, one of which is
interleukin-8 (IL-8) [30]. CXCR2 is overexpressed in the metastatic
breast cancer cell line MDA 231, in which hPTTG1 is overexpressed.
Interestingly, IL-8 overexpression in 231 cells had been reported aswell [31]. Thus, in these metastatic MDA 231 cells, there is IL-8/
CXCR2 autocrine signaling. This has signiﬁcant implications on
the tumor microenvironment, given the characteristic CXCR2
expression on cancer cells, endothelial cells, and tumor-associated
macrophages. IL-8/CXCR2 signaling can go through various path-
ways. One of these principal pathways goes through activation of
protein kinase B/Akt [32]. IL-8/CXCR2 signaling has also been shown
to induce the activation of the mitogen-activated protein kinase
cascade with the phosphorylation of Erk1/2 in cancer cells [33]. In
addition, IL-8/CXCR2 signaling has been reported to activate phos-
pholipase C. This in turn can generate diacylglycerol to mobilize
calcium and activate protein kinase C [34]. Furthermore, the Src
family kinases and focal adhesion kinase were found to be down-
stream targets of IL-8/CXCR2 signaling in certain cancer cell lines
[35]. IL-8/CXCR2 signaling was also found to activate members of
the Rho family of guanosine triphosphatases, promoting the poly-
merization of the actin cytoskeleton and retraction of cell cyto-
skeleton [36]. All these pathways usually result in activation of
transcription factors whose activity has been shown to promote cell
proliferation, cell spreading, motility, and invasion [37e39]. Our
studies showed that CXCR2 and GEFH1 were the direct targets of
hpttg1, and CXCR2 and GEFH1 could go through various pathways to
affect metastasis. Therefore, to elucidate the mechanisms of how
overexpressed hPTTG1 promotes tumor metastasis, it is important
to demonstrate which pathways hPTTG1 signals go through to drive
tumor metastasis.
3. hPTTG1 drives breast cancer metastasis through activation
of the GEF/RhoA signaling pathway
Using the loss-of-function approach (speciﬁc geneknockdownof
hPTTG1) on the human metastatic breast cancer cell line MDA
MB231 (231 for short) and the gain-of-function approach (ectopic
overexpression of hPTTG1) on the nonmetastatic breast cancer cell
line MCF7, we explored how the overexpressed hPTTG1 gene en-
hances the motility and invasiveness of cancer cell in vitro and
promotes cancer metastasis in vitro. Through reporter analysis, gel
mobility, and chromatin immunoprecipitation analysis, we know
hPTTG1 binds directly to the binding sites on the regulatory se-
quences of the GEFH1 gene, thus activating GEFH1, which in turn
activates its downstream effecter RhoA. Knockdown of hPTTG1 or
GEFH1 expression reduces the migratory and invasive abilities of
metastatic 231breast cells. Conversely, ectopic expressionof hPTTG1
or GEFH1 enhances the migratory and invasive ability of non-
metastaticMCF7 cells. These observed effectswere due to activation
of the GEFH1/RhoA signaling axis by overexpressed hPTTG1 to
modulate and remodel the dynamic of cytoskeletal structures.
Using a mouse model for breast cancer metastasis, we also
demonstrated that reducing the expression of hPTTG1 or GEFH1 in
231 cells by short hairpin RNA (shRNA) knockdown of these genes
would reduce the ability of the cancer cells to metastasize to the
lung. Reintroduction of GEFH1 to the hPTTG1 knockdown 231 cells
restores the metastatic ability of these 231 cells. When hPTTG1was
ectopically expressed in nonmetastatic MCF7 cells that were
transplanted into severe combined immunodeﬁciency (SCID) mice,
the metastatic outcomes did not follow our expectation that over-
expressed hPTTG1 would accelerate metastasis. Instead, prolifera-
tion of cancer cells was decreased, tumors that formed were
smaller, and progression of metastasis was delayed. These puzzling
results were eventually explained to be due to oncogene-induced
senescence (see the following section). Nevertheless, the activa-
tion of GEFH1/RhoA signaling axis by the overexpressed hPTTG1was
recapitulated in immunohistochemical studies of human tumor
samples; in aggressive breast carcinomas, the hPTTG1 gene
expression was positively correlated with GEFH1 expression. The
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4. The role of PTTG1-activated CXCR2 in breast cancer
metastasisdsenescence and inﬂammation (i.e., tumor
microenvironment and metastasis)
Like the oncogenes myc and Ras, hPTTG1 frequently induced
senescence when it is overexpressed in cells. We found that
ectopically overexpressed hPTTG1 in MCF7 could use at least two
pathways to activate CXCR2 and its ligands, IL-8 and Gro-a. It could
directly activate the CXCR2 signaling or it could activate nuclear
factor-kB (NF-kB) which, in turn, could activate IL-8 and Gro-a to
drive CXCR2 signaling. CXCR2 signaling induces senescence through
p21 expression. Thus, when CXCR2-speciﬁc shRNA was used to
reduce CXCR2 expression in hPTTG1-overexpressed MCF7 cells, p21
expression concomitantly decreases with cell release from senes-
cence. As mentioned earlier, when hPTTG1-overexpressed MCF7
cells were transplanted into SCID mice, much smaller tumors were
formed and tumor metastasis to the lung was delayed. If we
knocked down the expression of CXCR2 in hPTTG1-overexpressed
MCF7 cells and transplanted these cells into mice, both tumor
growth and metastasis were accelerated. These results strongly
suggest that if the senescence mechanism in tumor cells remains
intact, the overexpression of metastasis promoting hPTTG1 would
induce senescence. If the mechanism for enforcing senescence is
damaged or defective in tumor cells, the overexpression of hPTTG1
would drive tumor cells toward metastasis. This provides expla-
nation for the difference in metastatic behavior between 231 MCF7
cells. 231 cells have null functions in p53 among others, and
therefore the maintenance of senescence was lost, whereas in
MCF7 cells the functions of p53 and p21 are intact and thus
senescence is reinforced when hPTTG1 is ectopically expressed.
Although ectopic expression of hPTTG1 in MCF cells enforces
senescence through CXCR signaling, these cells appear to enhance
the migratory and invasive abilities of nonmetastatic MCF cells in
culture. Experiments conducted in SCID mice showed that the
hPTTG1-overexpressed MCF cells appeared to trigger an inﬂam-
matory reaction that recruited macrophages to create a microen-
vironment that favored and enhanced the metastatic ability of
MCF7 cells. It is very likely that the senescent MCF cells secrete
inﬂammatory cytokines that can attract and recruit inﬂammatory
cells to tumor sites. However, detailed mechanisms remain to be
illustrated. The examination of human tumor samples essentially
recapitulated what we observed in cell cultures and in mouse
model studies. Thus, it appears that overexpression of hPTTG1 in-
duces genetic stress to trigger a DNA damage response in cancer
cells. If the machinery of senescence maintenance, i.e., CXCR2/p21
signaling, remains intact, then cancer cells remain in a state of
senescence with retarded metastasis. However, if CXCR2/p21
signaling is defective, cancer cells move toward metastasis without
hindrance. In addition, the overexpression of hPTTG1 triggers a DNA
damage response, which activates NF-kB signaling to induce in-
ﬂammatory reactions that remodel a microenvironment favoring
and enhancing tumor metastasis. The results of these observations
have been reported elsewhere [42].
5. Implications
1. Cancer cells activate more than one pathway to promote
metastasis. Thus, a therapy that targets a cancer driver gene
may work for a short time but cancer cells may develop mu-
tations, and in addition, switch to other pathways. Therefore, it
is better to determine how many pathways are activated in a
particular cancer type (i.e., determine genetic background toprovide information about pathways, which tumor cells use to
enhance their metastatic potentials). The therapeutic method
can then be designed to target key genes in these pathways
simultaneously to eradicate all cancer cells before they are able
to develop mutations.
2. In addition to targeting oncogenic pathways or repairing
pathways alone, it would be helpful to develop inhibitors that
can block the crosstalk between cancers and cells that consti-
tute the tumor microenvironment.
3. Because hPTTG1 is overexpressed in most metastatic cancer
cells and blastic leukemia, providing these cancer cells a
driving force for metastasis, it will be very desirable to screen
for inhibitors that have high-afﬁnity binding for PTTG1. This
could interfere or block both the ability of PTTG1 to activate
genes involving tumorigenesis and the interacting proteins of
PTTG1, which are accomplices in tumor metastasis.
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